Agios Pharmaceuticals, Inc.
AGIO· Nasdaq
AGIOAgios Pharmaceuticals, Inc.
Filed Feb 23, 2023 · 10-K · 54 days after period end · 0001439222-23-000039
derived · Computed from the longer spans the company filed.
| Metric | Q4 2022dderived from reported figures | Q4 2021 | Q4 2020 | Q4 2019 |
|---|---|---|---|---|
| Revenue | $4.31M | $0.00 | $44.05M | $35.44M |
| Net Income | $36.53M | -$94.63M | -$97.66M | -$102.35M |
| EPS Diluted | — | -$1.74 | -$1.41 | -$1.60 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Agios Pharmaceuticals, Inc. · CIK 1439222 · Engraved from SEC EDGAR
ended Dec 31, 2022 · filed Feb 23, 2023 · 54 d after period end
